

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), May 6, 2020

OTHER RELEVANT INFORMATION

In accordance with the Article 227 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, **LABORATORIO REIG JOFRE, S.A.** ("Reig Jofre" o "the Company") submits hereafter press release on the beginning of a clinical study to reduce the incidence of COVID-19 and its severity in the event of infection.

Reig Jofre begins a clinical study to reduce the incidence of COVID-19 and its severity in the event of infection

- Reig Jofre is the force behind a clinical study to evaluate the efficacy of the *Manremyc*[®] food supplement for those health professionals who are most exposed to the risk of contracting COVID19
- Reig Jofre expects to obtain the results in October 2020. In the event of *Manremyc*[®] proving effective against COVID19, it could be supplied for general use very easily
- The study will be carried out in coordination with the Germans Trias i Pujol Research Institute (IGTP) together with the Institute for Research in Primary Care Jordi Gol

Barcelona (Spain), May 6, 2020, Reig Jofre, a pharmaceutical company listed on the Spanish continuous market, is to begin a double-blind clinical study among a group of 300 health professionals with a high risk of contracting COVID-19. The participants will be administered *Manremyc*[®], an oral food supplement based on heat-inactivated *Mycobacterium s. manresensis* bacilli, in order to assess its efficacy in reducing the incidence of SARS-CoV-2 infection and, in the event of infection, to demonstrate its capacity to reduce the severity of the infection.

Manremyc[®] is the result of the research and development work carried out over more than 10 years by the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP). Countries in which mass vaccination is employed against TB have been found to have a lower incidence of COVID-19, due to the corresponding stimulation of innate immunity. This property is also induced by *Manremyc*[®], in addition to an anti-inflammatory response in the lungs. The progression of a *Mycobacterium tuberculosis* infection to tuberculosis (TB) is due to an excessive inflammatory response. The administration of *Manremyc*[®] generates a balanced immune response which enables such inflammation in lung lesions to be avoided.



Scientific evidence suggests that *Manremyc*[®] could help minimize the possibilities of a SARS-CoV-2 infection progressing into a severe lung infection, given the similarity in the progress of the two diseases. In the event of *Manremyc*[®] proving effective against COVID19, it will imply having an additional resource that is easy to implement, given both its convenient posology (1 capsule per day for only 14 days) and its high tolerability.

The study, which will begin this May and is expected to produce results in October, will be led by Dr. Pere-Joan Cardona, from the Germans Trias i Pujol Research Institute (IGTP) together with the Jordi Gol i Gurina Institute for Research in Primary Care (IDIAPJGol). It will be carried out in health system workers exposed to SARS-CoV-2 infection at the Germans Trias i Pujol University Hospital and various primary care centres in the North and South Metropolitan area of Barcelona.

Reig Jofre closed 2019 with a turnover of 200 million Euros. During the last 5 years, the company has allocated 48 million euros to research programs, representing approximately 5% of annual sales. For the marketing of its developments, Reig Jofre has its own sales network in 7 countries in Europe and Southeast Asia and trade relations with more than 130 partners (distributors and licensees) in 72 countries on five continents.

Receive updated news about Reig Jofre by registering with the company's **subscription centre** via our corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a family-controlled pharmaceutical company listed on the Spanish Stock Exchange's continuous market and dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements from its four plants in Toledo (2), Barcelona and Malmö (Sweden). Reig Jofre structures its product development activity in three business areas: (1) *Pharmaceutical technologies* specialized in sterile and lyophilized injectables, and antibiotics derived from penicillin; (2) *Specialty Pharmacare* in dermatology; Joint Pain, and Women's Health (developed and produced internally), and (3) *Consumer Healthcare*, with products aimed at the consumer under the Forté Pharma brand, mainly in France, Belgium, Spain and Portugal, and other OTCs. Reig Jofre has more than 1000 employees, direct sales in 7 countries and more than 130 business partners in 72 countries around the world. The company closed 2019 with a turnover of 200 million Euros. Reig Jofre is listed the ticker RJF. Share capital: 76,062,457 shares

Further information

Inma Santa-Pau - Director of Communication and Investor Relations
Tel. (+34) 935 450 078 - inma.santapau@reigjofre.com
www.reigjofre.com